[Minutes, Advisory Committee to the Director GP-160 Meeting (1992: Bethesda, Maryland)]

99
1 information.
2 DR. HOTH: Okay. Maybe we'll do a duet.
3 Fred, I have the slides. If you'd put the red on and
4 go to Slide Number 76, please?
5 DR. VALENTINE: To address some of the
6 questions that Dani Bolognesi raised, the ACTG has
7 studies underway, one of which now is ACTG 214, which
8 will take individuals in whom we know responses can be
9 induced and compare, really evaluate both isolate
10 specificity and expression system specificity, if you
11 will.
12 For example, we have a baculovirus, gp
13 163b, and an MN, the MN being an isolate more nearly
14 similar to those affecting most individuals in the
15 United States.
16 You have a Genentech co-cell in a million
17 cellulite constant at 3b and MN, direct comparison.
18 You have a Chiron gp 120, which is also an MN, which
19 will have a different adjuvant. And then you have
20 alum control.
21 I might hasten to add that in all of these
22 trials, the individuals who receive either a hepatitis

NEAL R. GROSS
COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVENUE, N.W.
(202) 234.-4433 WASHINGTON, D.C. 20005 [phone]